title: Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.
abstract: A 5 year old boy developed severe weakness after receiving vincristine for treatment of acute lymphoblastic leukaemia. Although weakness improved after the discontinuation of vincristine, other symptoms suggestive of a neuropathy persisted. Neurophysiological and genetic analysis at age 8 years indicated that vincristine had induced symptoms of a hereditary sensory motor neuropathy type 1A, which had previously been asymptomatic; his genetically affected mother was also asymptomatic.
authors.affiliation: Department of Paediatrics & Neonatal Medicine, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0HN, UK. e.mercuri@ic.ac.uk
authors.forename: E
authors.initials: E
authors.lastname: Mercuri
authors.forename: J
authors.initials: J
authors.lastname: Poulton
authors.forename: J
authors.initials: J
authors.lastname: Buck
authors.forename: V
authors.initials: V
authors.lastname: Broadbent
authors.forename: M
authors.initials: M
authors.lastname: Bamford
authors.forename: H
authors.initials: H
authors.lastname: Jungbluth
authors.forename: A Y
authors.initials: AY
authors.lastname: Manzur
authors.forename: F
authors.initials: F
authors.lastname: Muntoni
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002607:Charcot-Marie-Tooth Disease / Q000139:chemically induced* / Q000235:genetics; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D014750:Vincristine / Q000009:adverse effects*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine